Correlation of OXA-1 and TEM-1 genes with antibiotic resistance to piperacillin/tazobactam in ESBL-producing Enterobacterales: insights from a multi-center analysis
Frontiers in Cellular and Infection Microbiology · 12.01.2026 · 15
DOI: 10.3389/fcimb.2025.1694724 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 12.01.2026. Verfasst von Edwin Kamau und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Area Laboratory Services, Tripler Army Medical Center, Honolulu, HI, United States. Hauptthemen laut MEDLINE: beta-Lactamases, Piperacillin, Tazobactam Drug Combination, Anti-Bacterial Agents, Escherichia coli. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The emergence of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae presents significant challenges in treating infections caused by these pathogens. This multi-center retrospective study investigated the prevalence of OXA-1 and TEM-1 genes in ESBL-producing E. coli and K. pneumoniae , along with their association with piperacillin/tazobactam susceptibility and additional antimicrobial resistance genes.
Methods
Clinical isolates were collected from three institutions as part of routine patient care: Tripler Army Medical Center (TAMC) in Hawaii, Madigan Army Medical Center (MAMC) in Washington, and Brooke Army Medical Center (BAMC) in Southern Texas. A total of 416 isolates were analyzed through genome sequencing and CLSI-guided susceptibility testing.
Results
OXA-1 and TEM-1 β-lactamase enzymes were present in 20.9% (73/349) and 38.7% (135/349) of the E. coli isolates, respectively. Relative risk analysis of non-susceptibility to piperacillin/tazobactam across isolates from the three study sites revealed a highly significant association for OXA-1 ( P < 0.001), whereas no significant associations were observed for TEM-1 ( P = 0.424) or the combination of OXA-1 and TEM-1 ( P = 0.082). When analyzed by institution, the relative risk of non-susceptibility to piperacillin/tazobactam remained highly significant for OXA-1 at TAMC and MAMC ( P < 0.001 for both) but was not significant at BAMC ( P = 0.21). OXA-1 and TEM-1-positive variants showed a significant association with genes conferring resistance to other antibiotics.
Conclusions
The OXA-1 gene plays a key role in resistance to piperacillin/tazobactam in ESBL-producing organisms, with geographic differences in non-susceptibility observed. Genetic profiling and localized data are crucial for optimizing antibiotic therapy and improving treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Area Laboratory Services, Tripler Army Medical Center, Honolulu, HI, United States.
- Adult Intensive Care Unit, Tripler Army Medical Center, Honolulu, HI, United States.
- Department of Clinical Investigation, Tripler Army Medical Center, Honolulu, HI, United States.
Zitieren
APA
Kamau, E., Wong, B. M., MacArthur, J. L., & Dombach, J. L. (2026). Correlation of OXA-1 and TEM-1 genes with antibiotic resistance to piperacillin/tazobactam in ESBL-producing Enterobacterales: insights from a multi-center analysis. Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1694724
Vancouver
Kamau E, Wong BM, MacArthur JL, Dombach JL. Correlation of OXA-1 and TEM-1 genes with antibiotic resistance to piperacillin/tazobactam in ESBL-producing Enterobacterales: insights from a multi-center analysis. Frontiers in Cellular and Infection Microbiology. 2026;15. doi:10.3389/fcimb.2025.1694724
BibTeX
@article{Kamau2026,
author = {Kamau, Edwin and Wong, Brendan M and MacArthur, John L and Dombach, Jamie L},
title = {Correlation of OXA-1 and TEM-1 genes with antibiotic resistance to piperacillin/tazobactam in ESBL-producing Enterobacterales: insights from a multi-center analysis},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {15},
doi = {10.3389/fcimb.2025.1694724}
}
EUVIMED